TopAlliance Biosciences
在场
TopAlliance Biosciences 的所有者是 Junshi Biosciences.
是其中之一......
Junshi Biosciences 是一家在股票代码 688180 (HK) 下上市的公司。
高管
生物技术
Junshi Biosciences 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Evommune 刚刚宣布为 115 筹款数百万美元。 (公布2024十一月4号).
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
生物技术 行业的其他推荐联系人
消息
TopAlliance Biosciences 的最新新闻稿
- Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
- Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19 | Eli Lilly and Company
- Junshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studies
- Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia
- Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint
- Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients
- Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study
- Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
- Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study
- Junshi Biosciences Announces Acceptance of NDA for VV116 in China
- View more press releases Close
通过电子邮件
